A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine
about
Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationSystems Toxicology: Real World Applications and Opportunities.Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variabilityThe role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsRetracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Dealing with the complex drug-drug interactions: towards mechanistic models.Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug DispositionThe Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs.Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins.Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.ABCG2 as a therapeutic target candidate for gout.Assessing the risk of alcohol-induced dose dumping from sustained-release oral dosage forms: in vitro-in silico approach.Role of Hepatic Drug Transporters in Drug Development.Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.
P2860
Q27312881-536FD501-72B5-4DAF-8CCD-738B299A5268Q28088352-7F20382E-8772-4F40-B539-178A479C55C3Q33577370-AF0FF369-58C9-4509-8DEE-69496776E15CQ33581531-E53583A8-8E3E-4646-AE58-DA25CF3F18C9Q33994570-66258296-AC39-48EC-8DBB-84CDE812E65CQ34574831-C927F2B3-7890-4158-B779-74C6BC77CC01Q35560052-15640264-E356-4178-A2FF-6E04ED13AAAAQ36025902-AD0B20DE-8DC8-4530-8EFB-35C24B3A9F23Q36233941-B7C021C6-8407-45BC-A0F5-1AABBA6CA114Q36806598-CD7EFB12-D87A-4B93-828F-59A55E000C5DQ36972804-01DFC77D-970F-42B4-89EB-820C0D5F6EB8Q37279044-71D16B00-D04B-4A43-9E75-DE2B9F1956A8Q37394474-33F92825-A478-4D86-B669-B5C762551E9AQ37660713-9E5B71E3-EC7E-44AE-AB11-7065AFE3CF21Q38233298-0AF7F49F-EB77-41ED-BAC4-68BE9C41D981Q38302225-8BBF1FC3-5004-40A4-AAC1-CB2C48D53E4AQ38768114-C668219F-DD6F-4B14-A6A7-E6881AE9F754Q38793280-AD9E0A76-7FC7-49A3-8749-A21AB368A73DQ38796858-4B467BA2-8462-4F04-B498-CDC8CDD59CFEQ38844656-13B15D4F-963F-4040-BA15-3AD3FBF45445Q39178447-A9380158-4604-4895-AAFF-A235AC9C722CQ39773424-E232FBF6-7E27-4521-9B7C-5F5D323DB075Q40358160-306D2265-B37C-4A8B-8649-E12C38D297FDQ40916355-B56D1C51-5F3D-4167-A484-C6FBDA96432AQ41150870-3685943B-9B91-4EB7-95EF-A043B8AA714AQ44737065-E80B8B1C-C87F-42C4-B337-06098B61ADFDQ45243894-8E636897-8C99-4154-B8F9-C5E7552709CEQ46942949-09A32E38-6C2B-4A2D-8B8F-3A63DF980198Q47592224-E9DF89A6-8031-4922-A99F-2A1939289387Q47770438-8C833146-41A8-4BEF-8B14-4B71FF5EE83DQ50086889-0AA58808-F7F6-4D44-AE00-6345EBF41723Q51659233-12AF60C4-0176-4D22-8878-8FEB454A3FF0Q55080883-79856E0C-1943-40C7-9BF1-D039848C6509Q55518566-DE90C68E-9AC3-4F29-885C-A03F19C5FF5C
P2860
A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A mechanistic framework for in ...... rosuvastatin and cyclosporine
@en
A mechanistic framework for in ...... rosuvastatin and cyclosporine.
@nl
type
label
A mechanistic framework for in ...... rosuvastatin and cyclosporine
@en
A mechanistic framework for in ...... rosuvastatin and cyclosporine.
@nl
prefLabel
A mechanistic framework for in ...... rosuvastatin and cyclosporine
@en
A mechanistic framework for in ...... rosuvastatin and cyclosporine.
@nl
P2093
P2860
P1476
A mechanistic framework for in ...... rosuvastatin and cyclosporine
@en
P2093
A Rostami-Hodjegan
K Rowland-Yeo
P2860
P2888
P356
10.1007/S40262-013-0097-Y
P577
2014-01-01T00:00:00Z